Glisolamide

Glisolamide

SCHEMBL38106

Cc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)no1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.73
TSHR P16473 3/20 0.73
BLM P54132 3/20 0.73
CYP2C9 P11712 3/20 0.73
CYP3A4 P08684 2/20 0.73
MAPT P10636 2/20 0.73
CYP2C19 P33261 2/20 0.73
HTR1A P08908 1/20 0.73
NFKB1 P19838 1/20 0.73
CNR1 P21554 1/20 0.73
ADRA1A P35348 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
PPARG P37231 7/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
ABCC8 Q09428 2/20 0.60
ALDH1A1 P00352 2/20 0.60
KCNH2 Q12809 2/20 0.60
ABCC3 O15438 2/20 0.60
ABCC4 O15439 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glisolamide SCHEMBL27735549 0.91 CYP3A4 (0.62) LMNATSHRBLMCYP2C9CYP3A4
Glisoxepide SCHEMBL28142826 0.87 LMNA (0.57) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL17094 0.84 TSHR (1.00) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL29366401 0.84 TSHR (1.00) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL1536893 0.84 TSHR (1.00) LMNATSHRBLMCYP2C9CYP3A4
Glisoxepide SCHEMBL48892 0.84 LMNA (0.55) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL27573879 0.83 TSHR (0.98) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL27728874 0.83 TSHR (0.98) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL28867262 0.83 TSHR (0.98) LMNATSHRBLMCYP2C9CYP3A4
Glipizide SCHEMBL2057153 0.83 TSHR (0.98) LMNATSHRBLMCYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2578 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322777-A1 N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER INC. (US) 2023-10-12 US claimed
US-10966993-B2 Pharmaceutical composition comprising a sulfonylurea drug and preparation method thereof JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2021-04-06 US claimed
US-20200353034-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC DRUG AS ACTIVE INGREDIENTS NOVMETAPHARMA CO., LTD. (KR) 2020-11-12 US claimed
US-10792280-B2 Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes NOVMETAPHARMA CO., LTD. (KR) 2020-10-06 US claimed
EP-3698801-A2 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC DRUG AS ACTIVE INGREDIENTS Novmetapharma Co., Ltd. (KR) 2020-08-26 EP claimed
CN-111246859-A Pharmaceutical composition for preventing or treating diabetes containing zinc salt, cyclodipeptide-histidine proline and antidiabetic drug as effective component 诺麦塔制药有限公司 2020-06-05 CN claimed
EP-3556371-A1 PHARMACEUTICAL COMPOSITION OF SULFONYLUREA DRUGS AND PREPARATION METHOD THEREFOR Jiangsu Aosaikang Pharmaceutical Co., Ltd (CN) 2019-10-23 EP claimed
EP-3498279-A1 PHARMACEUTICAL COMPOSITION COMPRISING AMODIAQUINE AND ANTI-DIABETES DRUG AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF DIABETES Novmetapharma Co., Ltd. (KR) 2019-06-19 EP claimed
US-20190175583-A1 PHARMACEUTICAL COMPOSITION COMPRISING AMODIAQUINE AND ANTI-DIABETES DRUG AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF DIABETES NOVMETAPHARMA CO., LTD. (KR) 2019-06-13 US claimed
US-10294225-B2 N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2019-05-21 US claimed
CN-1264302-A Treatment of diabetes with thiazolidinediones and sulfonylureas SMITHKLINE BEECHAM PLC (GB) 2000-08-23 CN claimed
CN-1263467-A Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor SMITHKLINE BEECHAM PLC (GB) 2000-08-16 CN claimed
WO-2000028989-A1 PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT SMITHKLINE BEECHAM P.L.C. (GB) 2000-05-25 WO claimed
EP-1001784-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOSIDASE INHIBITOR SMITHKLINE BEECHAM PLC (GB) 2000-05-24 EP claimed
EP-1001783-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE SMITHKLINE BEECHAM PLC (GB) 2000-05-24 EP claimed
WO-2000027434-A1 COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT SMITHKLINE BEECHAM P.L.C. (GB) 2000-05-18 WO claimed
EP-0998291-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA SMITHKLINE BEECHAM PLC (GB) 2000-05-10 EP claimed
WO-1999003477-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1999003478-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR SMITHKLINE BEECHAM P.L.C. (GB) 1999-01-28 WO claimed
WO-1999003476-A1 TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA SMITHKLINE BEECHAM PLC (GB) 1999-01-28 WO claimed